|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's range||117.00 - 119.00|
|52-week range||101.55 - 121.53|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||28.32|
|Earnings date||01 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||5.64 (4.75%)|
|Ex-dividend date||13 Jan 2022|
|1y target est||131.84|
FDA panel votes for Merck's (MRK) COVID-19 antiviral pill. AbbVie (ABBV) seeks approval for Skyrizi for Crohn's disease in Europe
The stock market is not in the holiday spirit lately. Jason Hawthorne (Teladoc Health): Shareholders in this virtual healthcare company have likely experienced a range of emotions over the past two years. The company's market cap has fallen to $16 billion.
AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.